The use of hormone-receptor-targeted treatment strategies is associated with an approximately 50% reduction in recurrences and a reduction in breast-cancer-attributed deaths by approximately 30%, and receptor status assessment has, therefore, become the single most important biomarker in early and advanced breast cancer. This evidence concerns the gene NR4A1 and breast cancer.